Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12184811 | 0.90 | KDM4E (0.68) | KDM4EMAPK1HIF1AEPHX1TSHR | |
| SCHEMBL3190326 | 0.89 | EPHX1 (0.61) | EPHX1TSHRALDH1A1 | |
| SCHEMBL13202309 | 0.88 | KDM4E (0.73) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL8107 | 0.83 | KDM4E (0.71) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL12448045 | 0.80 | EPHX1 (0.48) | KDM4EMAPK1HIF1AEPHX1TSHR | |
| SCHEMBL3646499 | 0.79 | — | — | |
| SCHEMBL12743892 | 0.79 | EPHX1 (0.41) | KDM4EMAPK1HIF1AEPHX1TSHR | |
| SCHEMBL423443 | 0.78 | ACHE (0.47) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL7252127 | 0.78 | EPHX1 (0.77) | KDM4EMAPK1HIF1AEPHX1TSHR | |
| SCHEMBL14433357 | 0.78 | EPHX1 (0.70) | KDM4EMAPK1HIF1AEPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016132247-A1 | FLUORO-ALCOHOL ADDITIVES FOR ORIENTATION CONTROL OF BLOCK COPOLYMERS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022782-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PIPERIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | KDM4E 660/4885MAPK1 3/4885HIF1A 580/4885 |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | KDM4E 1638/4885MAPK1 283/4885HIF1A 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.